A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia (Q34210712)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia (English)

1 reference

Europe PubMed Central

31 July 2017

0 references

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Danielle Coppola

1

1 reference

Europe PubMed Central

31 July 2017

Yanning Liu

2

1 reference

Europe PubMed Central

31 July 2017

Srihari Gopal

3

1 reference

Europe PubMed Central

31 July 2017

Bart Remmerie

4

1 reference

Europe PubMed Central

31 July 2017

Mahesh N Samtani

5

1 reference

Europe PubMed Central

31 July 2017

David W Hough

6

1 reference

Europe PubMed Central

31 July 2017

Isaac Nuamah

7

1 reference

Europe PubMed Central

31 July 2017

Ahmad Sulaiman

8

1 reference

Europe PubMed Central

31 July 2017

Gahan Pandina

9

1 reference

Europe PubMed Central

31 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

28 March 2012

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

12

1 reference

Europe PubMed Central

31 July 2017

26

1 reference

Europe PubMed Central

31 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-244x-12-26

0 references

Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Risperidone long-acting injection: a review of its long term safety and efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Treatment strategies to prevent relapse and encourage remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

The case for long-acting antipsychotic agents in the post-CATIE era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Improving patient outcomes in schizophrenia: achieving remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

5-HT2 antagonism and EPS benefits: is there a causal connection?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Some suggestions for measuring predictive performance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

A rating scale for extrapyramidal side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

A rating scale for drug-induced akathisia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

5 July 2018

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-12-26

21 January 2018

Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-12-26

21 January 2018

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-12-26

21 January 2018

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-12-26

21 January 2018

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-12-26

21 January 2018

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-12-26

21 January 2018

A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-12-26

21 January 2018

Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384238

28 October 2018

Guidelines for depot antipsychotic treatment in schizophrenia

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-12-26

21 January 2018

D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-244X-12-26

1 reference

Europe PubMed Central

31 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34210712&oldid=1752742080"